Journal of Clinical & Experimental Immunology(JCEI)

TANLUN Research Institute for Clinical Management of Cancer, TANLUN Medical Research Inc., Beijing, China

Publications

• Research Article   
  Survival and Concomitant Antitumor Immunity in Cancer
  Author(s): Kangla Tsung*, Zhang Xu, Zhang Hui and TANLUN Research Participants Group
  
  What determines the survival time in a cancer case? An obvious aspect is the malignancy of the tumor. Based on our clinical observation, this so-called malignancy includes three aspects: 1) The mode of tumor replication, i.e., how rapidly a tumor replicates; 2) The ability to form distant metastasis; and 3) The ability to cause symptoms, often related to the ability to drive local inflammation. But tumor malignancy alone does not seem to correlate with cancer survival. Another factor contributing equally critical or even more critical to cancer survival is often ignored. It is the status of host antitumor immunity. Tumor malignancy is only the determinant factor for cancer survival when concomitant antitumor immunity is absent in a case. With a strong antitumor immunity, regardless of tumor malignancy, a case is likely to survive much longer than that of a case with a week or none ant.. Read More»
  

  Abstract HTML PDF